Nuclear factor kappa-light-chain-enhancer of activated B cells and Extracellular signal-regulated kinase signaling pathway (NF-κB and ERK signaling)

The NF-κB and ERK signaling pathways in bone marrow-derived dendritic cells (BMDCs) represent a critical regulatory axis for the innate and adaptive immune response (Source: PubMed, PMID: 30214458). NF-κB is a primary transcription factor responsible for the expression of pro-inflammatory cytokines and cell survival genes, while ERK is a key component of the MAPK pathway that translates extracellular signals into cellular responses (Source: UniProt, P19838, P27361). In BMDCs, the synergistic activation of these pathways is essential for dendritic cell maturation, which involves the upregulation of MHC II and co-stimulatory molecules necessary for T-cell activation (Source: PubMed, PMID: 25631203). Dysregulation of this signaling network is frequently observed in inflammatory and autoimmune conditions, where overactive BMDCs drive pathological immune responses (Source: Nature Reviews Immunology, doi:10.1038/nri.2017.115). Consequently, while the pathway itself is not a single molecular target, its constituent proteins like MEK and IKK are major focal points for therapeutic intervention in oncology and immunology (Source: PubChem, CID: 5282230).

Other names

NF-kappaB and MAPK/ERK pathwayNF-kB/ERK signaling in BMDCsPro-inflammatory signaling in dendritic cellsNF-kappaB and ERK1/2 signaling

Inhibition of the IKK complex or the proteasome to prevent NF-κB nuclear translocation; inhibition of MEK1/2 kinases to prevent the phosphorylation and activation of ERK1/2 (Source: PubMed, PMID: 28848666).